等待开盘 05-20 09:30:00 美东时间
+0.935
+2.23%
今日重点评级关注:HC Wainwright & Co.:维持Protara Therapeutics"买入"评级,目标价从23美元升至27美元;BTIG:维持Black Diamond Therapeutic"买入"评级,目标价从10美元升至11美元
04-30 19:24
Axogen (NASDAQ:AXGN) released first-quarter financial results and hosted an ear...
04-28 22:18
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
04-28 22:06
Axogen shares are trading higher after the company reported better-than-expecte...
04-28 21:07
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
Axogen (NASDAQ:AXGN) FY2026 Revenue expected to be at least $270.000M vs $266.219M Est
04-28 19:03
Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 450 percent increase over losses of $(0.02) per share from the same period last year. The company
04-28 19:01
今日重点评级关注:花旗:维持Pegasystems"买入"评级,目标价从70美元升至71美元;巴克莱:维持曼哈顿联合软件"超配"评级,目标价从236美元升至239美元
04-24 12:10
Lake Street analyst Frank Takkinen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $40 to $50.
04-24 03:03
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Axogen业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - Q4营收5,990万美元,同比增长21.3% - 全年营收2.252亿美元,同比增长20.2% - 三个核心市场均实现双位数增长 **盈利能力:** - Q4毛利润4,440万美元,毛利率74.1%(同比下降2个百分点) - 全年毛利润1.674亿美元,毛利率74.3%(同比下降1.5个百分点) - 毛利润受FDA BLA批准相关的一次性成本影响,Q4影响190万美元,全年影响占比0.9% **净利润:** - Q4净亏损1,320万美元(每股亏损0.
02-25 12:24